Multiple Myeloma also known as Kahler’s disease is a type of blood cancer that affects plasma cells a subtype of white blood cells. Plasma cells are antibody generating cells. When an individual suffers from multiple myeloma these plasma cells produce immunoglobins in excess which damage the other organs of the body. Multiple Myeloma is usually rare and based on the effect on the body it is categorized into two: an indolent myeloma, usually develops slowly and doesn’t cause bone tumors. There is only slight increase in (monoclonal) M plasma cells and protein, and a solitary plasmacytoma, typically form tumors in bone. Multiple myeloma is not curable and treatment can only slow down the cancer progression. However, CAR T-Cell therapy is a novel therapy which make use of genetically engineered T cell to make chimeric antigen protein which in turn identify the target protein on cancerous cells and kill them. CAR T-cell treatments for multiple myeloma target a protein called B-cell maturation antigen (BCMA), present on the surface of myeloma cells but not healthy cells.
DelveInsight’s, “CAR T-Cell Therapy for Multiple Myeloma Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in CAR T-Cell Therapy for Multiple Myeloma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Request for free Sample Report: https://www.delveinsight.com/sample-request/car-t-cell-therapy-for-multiple-myeloma-pipeline-insight
Some of CAR T-Cell Therapy for Multiple Myeloma Companies are:
DelveInsight’s CAR T-Cell Therapy for Multiple Myeloma report covers around 5+ products under different phases of clinical development like:
CAR T-Cell Therapy for Multiple Myeloma Therapies are:
Current CAR T-Cell Therapy for Multiple Myeloma Treatment Scenario and CAR T-Cell Therapy for Multiple Myeloma Emerging Therapies:
Table of Contents:
Introduction
Executive Summary
CAR T-Cell Therapy for Multiple Myeloma: Overview
Pipeline Therapeutics
Therapeutic Assessment
CAR T-Cell Therapy for Multiple Myeloma – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
CAR T-Cell Therapy for Multiple Myeloma Collaboration Deals
Early Stage Products (Phase I)
PHE 885: Novartis
Drug profiles in the detailed report…..
Pre-clinical Stage
JNJ-68284528: Janssen Biotech
Pre-clinical and Discovery Stage Products
Inactive Products
CAR T-Cell Therapy for Multiple Myeloma Key Companies
CAR T-Cell Therapy for Multiple Myeloma Key Products
CAR T-Cell Therapy for Multiple Myeloma- Unmet Needs
CAR T-Cell Therapy for Multiple Myeloma- Market Drivers and Barriers
CAR T-Cell Therapy for Multiple Myeloma- Future Perspectives and Conclusion
CAR T-Cell Therapy for Multiple Myeloma Analyst Views
Appendix
Request for Detailed TOC @ https://www.delveinsight.com/sample-request/car-t-cell-therapy-for-multiple-myeloma-pipeline-insight
About DelveInsight DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: +19193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/report-store/car-t-cell-therapy-for-multiple-myeloma-pipeline-insight